Stay updated with breaking news from Tissue Factor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate VYVGART® was launched in September 2023 in China and we...
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Metastatic Colorectal Cancer.
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Bladder Cancer.
Following an extension of its partnership agreement with PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, Aptamer Group has announced the development of new drug conjugates for use as precision chemotherapeutics. Click to read more...
Investegate announcements from Aptamer Group PLC, Aptamer Group and PinotBio extend collaboration